Show simple item record

dc.contributor.authorThompson, Craig Pen
dc.contributor.authorGrayson, Nicholas Een
dc.contributor.authorPaton, Robert Sen
dc.contributor.authorBolton, Jai Sen
dc.contributor.authorLourenço, Joséen
dc.contributor.authorPenman, Bridget Sen
dc.contributor.authorLee, Lian Nen
dc.contributor.authorOdon, Valerieen
dc.contributor.authorMongkolsapaya, Juthathipen
dc.contributor.authorChinnakannan, Senthilen
dc.contributor.authorDejnirattisai, Wanwisaen
dc.contributor.authorEdmans, Matthewen
dc.contributor.authorFyfe, Alexen
dc.contributor.authorImlach, Carolen
dc.contributor.authorKooblall, Kreepaen
dc.contributor.authorLim, Nicholasen
dc.contributor.authorLiu, Changen
dc.contributor.authorLópez-Camacho, Césaren
dc.contributor.authorMcInally, Carolen
dc.contributor.authorMcNaughton, Anna Len
dc.contributor.authorRamamurthy, Narayanen
dc.contributor.authorRatcliff, Jeremyen
dc.contributor.authorSupasa, Piyadaen
dc.contributor.authorSampson, Oliveren
dc.contributor.authorWang, Beibeien
dc.contributor.authorMentzer, Alexander Jen
dc.contributor.authorTurner, Marcen
dc.contributor.authorSemple, Malcolm Gen
dc.contributor.authorBaillie, Kennethen
dc.contributor.authorISARIC4C Investigators,en
dc.contributor.authorHarvala, Helien
dc.contributor.authorScreaton, Gavin Ren
dc.contributor.authorTemperton, Nigelen
dc.contributor.authorKlenerman, Paulen
dc.contributor.authorJarvis, Lisa Men
dc.contributor.authorGupta, Sunetraen
dc.contributor.authorSimmonds, Peteren
dc.date.accessioned2021-01-19T00:31:08Z
dc.date.available2021-01-19T00:31:08Z
dc.date.issued2020-10en
dc.identifier.issn1025-496X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/316374
dc.description.abstractBackgroundThe progression and geographical distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United Kingdom (UK) and elsewhere is unknown because typically only symptomatic individuals are diagnosed. We performed a serological study of blood donors in Scotland in the spring of 2020 to detect neutralising antibodies to SARS-CoV-2 as a marker of past infection and epidemic progression.AimOur objective was to determine if sera from blood bank donors can be used to track the emergence and progression of the SARS-CoV-2 epidemic.MethodsA pseudotyped SARS-CoV-2 virus microneutralisation assay was used to detect neutralising antibodies to SARS-CoV-2. The study comprised samples from 3,500 blood donors collected in Scotland between 17 March and 18 May 2020. Controls were collected from 100 donors in Scotland during 2019.ResultsAll samples collected on 17 March 2020 (n = 500) were negative in the pseudotyped SARS-CoV-2 virus microneutralisation assay. Neutralising antibodies were detected in six of 500 donors from 23 to 26 March. The number of samples containing neutralising antibodies did not significantly rise after 5-6 April until the end of the study on 18 May. We found that infections were concentrated in certain postcodes, indicating that outbreaks of infection were extremely localised. In contrast, other areas remained comparatively untouched by the epidemic.ConclusionAlthough blood donors are not representative of the overall population, we demonstrated that serosurveys of blood banks can serve as a useful tool for tracking the emergence and progression of an epidemic such as the SARS-CoV-2 outbreak.
dc.format.mediumPrinten
dc.languageengen
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectISARIC4C Investigatorsen
dc.subjectHumansen
dc.subjectPneumonia, Viralen
dc.subjectCoronavirus Infectionsen
dc.subjectAntibodies, Viralen
dc.subjectEnzyme-Linked Immunosorbent Assayen
dc.subjectNeutralization Testsen
dc.subjectPopulation Surveillanceen
dc.subjectPrevalenceen
dc.subjectCluster Analysisen
dc.subjectSensitivity and Specificityen
dc.subjectSeroepidemiologic Studiesen
dc.subjectInhibitory Concentration 50en
dc.subjectModels, Immunologicalen
dc.subjectAdulten
dc.subjectBlood Donorsen
dc.subjectUrban Populationen
dc.subjectScotlanden
dc.subjectFemaleen
dc.subjectMaleen
dc.subjectAntibodies, Neutralizingen
dc.subjectPandemicsen
dc.subjectGeography, Medicalen
dc.subjectBetacoronavirusen
dc.subjectCOVID-19en
dc.subjectSARS-CoV-2en
dc.titleDetection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.en
dc.typeArticle
prism.issueIdentifier42en
prism.publicationDate2020en
prism.publicationNameEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinen
prism.volume25en
dc.identifier.doi10.17863/CAM.63484
dcterms.dateAccepted2020-08-11en
rioxxterms.versionofrecord10.2807/1560-7917.es.2020.25.42.2000685en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2020-10en
dc.contributor.orcidKooblall, Kreepa [0000-0001-9547-2067]
dc.contributor.orcidSampson, Oliver [0000-0001-8727-0588]
dc.contributor.orcidScreaton, Gavin R [0000-0002-3549-4309]
dc.contributor.orcidTemperton, Nigel [0000-0002-7978-3815]
dc.identifier.eissn1560-7917
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (MR/P502091/1�)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International